QRISK2, % 10-yr risk |
Attendees | 29 672 | 6.7 ± 5.9 | 6.2 ± 5.3 | −0.48 (−0.50 to −0.46) | −0.29 (−0.31 to −0.27) | −0.21 (−0.24 to −0.19) |
Nonattendees | 109 116 | 5.1 ± 5.3 | 4.9 ± 5.0 | −0.19 (−0.19 to −0.18) | | |
Systolic BP, mm Hg |
Attendees | 29 672 | 131.9 ± 17.4 | 130.0 ± 12.7 | −1.92 (−2.09 to −1.75) | −2.72 (−2.88 to −2.56) | −2.51 (−2.77 to −2.25) |
Nonattendees | 109 116 | 128.5 ± 13.6 | 129.3 ± 11.3 | 0.79 (0.73 to 0.86) | | |
Diastolic BP, mm Hg |
Attendees | 29 672 | 80.2 ± 10.5 | 78.5 ± 7.7 | −1.71 (−1.82 to −1.60) | −1.74 (−1.84 to −1.64) | −1.46 (−1.62 to −1.29) |
Nonattendees | 109 116 | 78.7 ± 8.2 | 78.7 ± 6.7 | 0.02 (−0.01 to 0.07) | | |
Body mass index |
Attendees | 29 672 | 27.7 ± 5.1 | 27.7 ± 5.0 | 0.01 (−0.003 to 0.02) | −0.28 (−0.30 to −0.27) | −0.27 (−0.34 to −0.20) |
Nonattendees | 109 116 | 26.9 ± 4.1 | 27.2 ± 4.0 | 0.30 (0.29 to 0.30) | | |
Total cholesterol, mmol/L |
Attendees | 29 672 | 5.5 ± 1.0 | 5.3 ± 0.8 | −0.21 (−0.22 to −0.20) | −0.20 (−0.20 to −0.19) | −0.15 (−0.18 to −0.13) |
Nonattendees | 109 116 | 5.3 ± 0.6 | 5.3 ± 0.6 | −0.01 (−0.01 to −0.01) | | |
Smoking prevalence, % of group |
Attendees | 29 672 | 17.9 | 16.3 | −1.60 (−1.80 to −1.39) | −0.22 (−0.46 to 0.01) | −0.11 (−0.35 to 0.13) |
Nonattendees | 109 116 | 22.2 | 20.8 | −1.37 (−1.48 to −1.26) | | |
Statin prescribed, % of group |
Attendees | 29 672 | 9.7 | 15.3 | 5.60 (5.29 to 5.90) | 4.40 (4.17 to 4.62) | 3.83 (3.52 to 4.14) |
Nonattendees | 109 116 | 3.1 | 4.3 | 1.20 (1.11 to 1.28) | | |
Antihypertensive prescribed, % of group |
Attendees | 29 672 | 4.8 | 9.9 | 5.05 (4.76 to 5.33) | 2.45 (2.20 to 2.71) | 1.37 (1.08 to 1.66) |
Nonattendees | 109 116 | 1.8 | 4.4 | 2.59 (2.48 to 2.70) | | |